Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis is a clinical trial[1].
Key Facts
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis is in the country of United Kingdom[2].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's instance of is recorded as clinical trial[3].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's start time is recorded as +2013-04-30T00:00:00Z[4].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's end time is recorded as +2014-09-30T00:00:00Z[5].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's sponsor is recorded as Queen Mary University of London[6].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's main subject is recorded as multiple sclerosis[7].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's main subject is recorded as sclerosis[8].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's number of participants is recorded as {'unit': '1', 'amount': '+23'}[9].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's title is recorded as A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI[10].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's short name is recorded as INSPIRE[11].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[12].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's ClinicalTrials.gov ID is recorded as NCT01767701[13].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+55'}[14].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's clinical trial phase is recorded as phase II clinical trial[15].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's research site is recorded as The Royal London Hospital[16].
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis's study type is recorded as interventional study[17].